CCR5Δ32 Genotype Leads to a Th2 Type Directed Immune Response in ESRD Patients

Friso L. H. Muntinghe1*, Wayel H. Abdulahad2, Minke G. Huitema2, Jeffrey Damman3, Marc A. Seelen3, Simon P. M. Lems4, Bouke G. Hepkema4, Gerjan Navis3, Johanna Westra2

1 Internal Medicine, Vascular Medicine, University Medical Center Groningen, Groningen, The Netherlands, 2 Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands, 3 Internal Medicine, Nephrology, University Medical Center Groningen, Groningen, The Netherlands, 4 Laboratory Medicine, Transplantation Immunology, University Medical Center Groningen, Groningen, The Netherlands

Abstract

Background: In patients with end stage renal disease (ESRD) we observed protection from inflammation-associated mortality in CCR5Δ32 carriers, leading to CCR5 deficiency, suggesting impact of CCR5Δ32 on inflammatory processes. Animal studies have shown that CCR5 deficiency is associated with a more pronounced Th2 type immune response, suggesting that in human CCR5Δ32 carriers the immune response may be more Th2 type directed. So, in the present study we determined the Th1-Th2 type directed immune response in ESRD patients carrying and not carrying the CCR5Δ32 genetic variant after stimulation.

Methodology/Principal Findings: We tested this hypothesis by determining the levels of IFN-γ and IL-4 and the distribution of Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T cells and regulatory T cells (Tregs) after stimulation in ESRD patients with (n = 10) and without (n = 9) the CCR5Δ32 genotype. The extracellular levels of IFN-γ and IL-4 did not differ between CCR5Δ32 carriers and non-carriers. However, based on the intracellular cytokine profile the percentages IL-4 secreting CD4+ and CD8+ T cells carrying the CCR5Δ32 genotype were significantly increased (p = 0.02, respectively p = 0.02) compared to non-carriers, indicating a more Th2 type directed response. Based on their intracellular cytokine profile the percentages IFN-γ and IL-17 secreting T cells did not differ between carriers and non-carriers nor did the percentage Tregs, indicating that the Th1, Th17 and T regulatory response was not affected by the CCR5Δ32 genotype.

Conclusions/Significance: This first, functional human study shows a more pronounced Th2 type immune response in CCR5Δ32 carriers compared to non-carriers. These differences may be involved in the previously observed protection from inflammation-associated mortality in ESRD patients carrying CCR5Δ32.

Introduction

Genetic variability in the chemokine cascades could potentially influence disease outcomes by modifying inflammatory processes. CC-chemokine receptor 5 (CCR5) is one of the chemokine receptors. It is expressed on T cells and monocytes and it is important for recruitment [1,2]. Several polymorphisms have been described for CCR5. The CCR5Δ32 genetic variant is located on the chromosome 3p21 and consists of a 32-basepair deletion in the open reading frame. It effectively results in functional CCR5 deficiency by absence of CCR5 membrane expression [3]. We observed protection from inflammation-associated mortality in carriers of the deletion 32 allele in end stage renal disease (ESRD), suggesting impact of CCR5Δ32 on the inflammatory process of atherosclerosis [4]. Also in other human populations, characterized by high cardiovascular risk, the presence of the CCR5Δ32 genotype has been associated with better outcome [5–8].

In chronic inflammatory processes like atherosclerosis T cells play an important role. Both CD4+ T cells and to a lesser extent CD8+ T cells are present in atherosclerotic lesions [9–12]. CD4+ T helper cells can differentiate into three effector lineages based on their cytokine expression: IFN-γ/TNF-α producers (Th1), IL-4 producers (Th2) and IL-17 producers (Th17) [12,13]. In addition, a small fraction of CD4+ T cells can develop into cells with a regulatory function (Tregs) that are defined by their co-expression of high levels of surface CD25 and intracellular transcription factor forkhead box P3 (FoxP3). These Tregs have the remarkable ability to suppress the proliferation and effector function of other T cells [9,12]. As with CD4+ T cells, CD8+ T cells can differentiate to cytotoxic (Tc)1 or Tc2 cell subsets, secreting predominantly Th1 or Th2 cytokines respectively [13].

Atherosclerotic inflammation is regarded as a (partly) Th1 driven condition [12]. The CCR5 receptor is highly expressed on T-lymphocytes, on both CD4+ T and CD8+ T cells [2,11]. In atherosclerotic mice CCR5 deficiency is associated with a more pronounced Th2 type immune response and less TNF-α and IFN-γ production hereby counteracting the Th1 directed Th1/Th2 disequilibrium of atherosclerotic inflammation [14–17].
These data fuel the hypothesis that the immune response in carriers of the CCR5Δ32 genotype is more Th2 type directed. Such differences in response might play a role in the protection against inflammation-associated mortality in ESRD in carriers of the CCR5Δ32 genotype. To test this hypothesis, we studied the cell mediated immune responses in peripheral mononuclear cells (PBMCs) in ESRD patients. We first determined the extracellular levels of IFN-γ and IL-4 after stimulation of PBMCs, and second the distribution of Th1, Th2 and Th17 directed circulating CD4+ and CD8+ T cells, based on their intracellular cytokine profile after stimulation, and the percentage of Treg in ESRD patients with and without the CCR5Δ32 genotype.

Methods

Objectives

The objective of the present study was to determine possible differences in cell mediated immune response between ESRD carriers and non carriers of the CCR5Δ32 genotype. To test this hypothesis, we first determined the IFN-γ and IL-4 levels after stimulation of peripheral mononuclear cells (PBMCs) and second the distribution of Type-1, Type-2 and Type-17 directed circulating CD4+ and CD8+ T cells, based on their intracellular cytokine profile, as well as the frequency of FoxP3+ regulatory T cells.

Participants

Biosamples and data from twenty patients with ESRD were included in this study. These patients were part of an ESRD cohort from a single kidney transplant centre in the Netherlands (University Medical Center Groningen), in whom data and biosamples were collected prior to kidney transplantation. As part of a larger genotyping project, all patients were genotyped as described below. For the current project we randomly selected five homo- and five heterozygous carriers from the cohort. Ten wild type patients were matched with carriers according to time of inclusion, hereby creating similar preservation conditions.

Genotyping

The genotypes were determined with a PCR-based allelic discrimination assay using primers (Life Technologies) and allele-specific probes (PE Biosystems) as described previously [18]. Patients were grouped by CCR5 genotype, namely those homozygous for the major allele (non-carriers) and those with 1 or 2 deletion alleles (carriers). Patients with one or two deletion alleles were grouped together, as it has been demonstrated that presence of one deletion allele is sufficient to compromise CCR5 function [3].

Sample preparation and thawing

Heparinized venous blood was obtained from ESRD-patients who gave their informed consent. PBMCs were separated by conventional Ficoll gradient and frozen in 10% DMSO in FCS and stored in liquid nitrogen. PBMCs were thawed and washed twice with RPMI 1640 media (Cambrex Bio Science, Verviers, Belgium), supplemented with 10% heat inactivated fetal calf serum and 50 μg/mL gentamycin (Gibco, Scotland, UK).

Determination of extracellular cytokine by ELISA

Thawed PBMCs were cultured in a 5 mL polypropylene tubes (BD Biosciences) at 2.5×10^6 cells/mL per tube, and stimulated with 40 nM phorbol myristate acetate (PMA; Sigma-Aldrich, Steinheim, Germany) and 2 nM calcium ionophore (Sigma-Aldrich). Culture supernatants were collected over a period of 24 hours to determine the extracellular levels of IFN-γ, and IL-4 cytokines.

Cytokine levels of IFN-γ and IL-4 were measured by commercial sandwich enzyme linked immunoassay (ELISA) kits (Pehlke Compact, Sanquin, Amsterdam, The Netherlands), according to the instructions of the manufacturer.

Determination of intracellular cytokine by flow cytometry

The following conjugated antibodies were used in flow cytometry: allophycocyanin (APC)–Cy7–conjugated anti-CD69, peridinin-chlorophyll protein (PerCP)–conjugated anti-CD8, phycoerythrin (PE)–Cy7–conjugated anti-IL-4, and Alexa Fluor 700–conjugated anti-IFN-γ (all from Becton & Dickinson, Amsterdam, The Netherlands). Alexa Fluor 488–conjugated anti-IL-17, Alexa Fluor 647–conjugated anti-TNF-α, and eFluor657TM-conjugated anti-CD3 were obtained from eBioscience (San Diego, CA). To determine the frequency of T cell subsets by measuring intracellular cytokine production, cells were stimulated for 4 hours with 40 nM PMA and 2 nM calcium ionophore. Brefeldin A (10 μg/mL) was added to inhibit cytokine release. After stimulation, cells were washed in wash buffer (phosphate buffered saline, 5% fetal bovine serum, 0.1% sodium azide; Merck, Darmstadt, Germany) and stained with eFluor 605-conjugated anti-CD3, PerCP–conjugated anti-CD8 and APC-Cy7–conjugated anti-CD69 for 15 minutes at room temperature. Cells were fixed with 100 μl Reagent A (CalTAG, An Der Grab, Austria) for 15 minutes. After washing, the pellet was resuspended in 100 μl permeabilization Reagent B (CalTAG) and labeled with PE-Cy7–conjugated anti-CD4, Alexa Fluor 700–conjugated anti-IFN-γ, Alexa Fluor 647–conjugated anti-TNF-α, Alexa Fluor 488–conjugated anti-IL-17, and APC-Cy7–conjugated anti-CD69 for 30 minutes in the dark. After staining, the cells were washed and immediately analyzed on a FACS-LSRII flow cytometer (Becton Dickinson). Seven-color flow cytometric acquisition was performed using FACSDiva software (Becton Dickinson). For all flow cytometry analyses, data were collected for 2×10^5 cells and plotted using the Win-List software package (Verity Software House, Topsham, ME). Because stimulation reduces surface expression of CD4 on T cells, CD4+ T cells were identified indirectly by gating on CD3+ and CD8– lymphocytes, whereas CD8+ T cells were identified by directly gating on CD3+ and CD8+ lymphocytes. Subsets of activated CD4+ and CD8+ T cells in response to mitogenic stimulation were evaluated by double expression of activation marker CD69 and intracellular cytokine production of IFN-γ (for type-1) or IL-17 (for type-17) or IL-4 (for type-2). The unstained samples were used as a guide for setting the linear gates to delineate positive and negative populations.

Determination of regulatory T cell frequencies

PBMCs were washed with cold PBS (pH 7.2) and incubated with appropriate concentrations of PerCP-conjugated anti-CD4, FITC-conjugated anti-CD3 and PE-conjugated anti-CD25 (all purchased from BD) for 30 min at 4°C in the dark. Cells were then washed with cold PBS, followed by fixation and permeabilization in Fix/Perm buffer (FoxP3 staining kit, eBioscience, Uithoorn, The Netherlands) for 45 min at 4°C. Subsequently, cells were washed with cold permeabilization buffer (FoxP3 staining kit, eBioscience, Uithoorn, The Netherlands). To block nonspecific binding, normal rat serum was added for 10 min, followed by the addition of APC-conjugated rat anti-human FoxP3 (eBioscience, Uithoorn, The Netherlands). After incubation for 30 min at 4°C, the cell suspension was washed twice with cold permeabilization buffer, and immediately analyzed on FACS-Calibur (BD). Data were collected for 2×10^5 cells and plotted using the Win-List
software package (Verity Software House, Topsham, ME). Positively and negatively stained populations were calculated by quadrant dot-plot analysis, determined by the isotype matched control antibodies of irrelevant specificity (obtained from BD and eBioscience).

Ethics
All patients gave written informed consent and the local medical ethics committee from the University Medical Center Groningen (METc UMC Groningen), the Netherlands, gave their approval.

Statistical methods
Patients were grouped by CCR5 genotype, namely those homozygous for the major allele (non-carriers) and those with 1 or 2 deletion alleles (carriers). The latter were grouped together, as it has been demonstrated that presence of one deletion allele is sufficient to compromise CCR5 function [3]. Data are presented as the median. The nonparametric Mann-Whitney U test was used to compare data from patients with and without the CCR5Δ32 genotype. Differences were considered statistically significant at 2-sided p values less than 0.05.

Results
Patients
From the 20 patients who were included in this study 1 stimulation test failed due to the fact that the T cells could not be stimulated. Further statistical analyses were performed on the remaining 19 patients. Baseline characteristics are shown in Table 1. There were no statistically significant differences in baseline characteristics between the 2 genotype groups.

Extracellular cytokines of type-1 and type-2 T cells
To assess the functional capacity of the responding PBMCs the total amount of IFN-γ and IL-4 after stimulation was determined. As shown in Figure 1, the levels of extracellular IFN-γ and IL-4 were not statistically significant different between carriers and non carriers of the CCR5Δ32 genotype.

Intracellular cytokines of type-1, type-2, and type-17 T cells
To elucidate the functional phenotype of the CD4+ and CD8+ T cells responding to stimulation, activated T cells were gated and evaluated for expression of the activation marker CD69 versus intracellular expression of the cytokines IFN-γ, IL-17 and IL-4. The results are shown in Figure 2 and 3. The percentages IL-4 secreting CD4+ and CD8+ T cells from patients with the CCR5Δ32 genotype was significantly (p = 0.02, respectively p = 0.02) increased compared to patients not carrying the CCR5Δ32 genotype, indicating a more Th2 type directed response. The percentages IFN-γ secreting CD4+ and CD8+ T cells did not significantly differ between carriers and non carriers of CCR5Δ32, meaning the Th1 and Th17 response did not differ between these 2 groups. Comparing the CCR5Δ32 homozygous and heterozygous CD4+ and CD8+ T cells showed no significant differences.

Frequencies of regulatory T cells
To address the question whether differences in Tregs frequencies influence the distribution of T cell subsets between CCR5Δ32 carriers and non carriers, FoxP3+CD25HighCD4+ T cells were analyzed in both groups. No significant differences were found between the 2 genotype groups (Figure 4). It seems, therefore, that

Table 1. Baseline characteristics.

|                          | CCR5 wild type (n = 9) | CCR5 deletion 32 (n = 10) |
|--------------------------|------------------------|---------------------------|
| Gender; male             | 4 (44.4)               | 7 (70.0)                  |
| Age (year)               | 51 (14)                | 51 (13)                   |
| Primary kidney disease   |                        |                           |
| Renal vascular disease   | 3                      | 3                         |
| and hypertension         |                        |                           |
| Diabetes mellitus        | 1                      | 0                         |
| Cystic kidney disease    | 1                      | 3                         |
| Pyelonephritis           | 1                      | 1                         |
| Primary oxalosis         | 1                      | 0                         |
| Unknown                  | 2                      | 3                         |
| Dialysis duration (days) | 1570 (880)             | 1005 (734)                |
| Hemodialysis             | 5 (55.6)               | 4 (44.4)                  |
| Body Mass Index          | 26 (4.94)              | 25 (3.21)                 |
| Systolic bloodpressure   | 147 (19)               | 138 (10)                  |
| (mmHg)                   |                        |                           |
| Diastolic bloodpressure  | 86 (8)                 | 86 (9)                    |
| (mmHg)                   |                        |                           |

Data are presented as number (percentage), mean (SD).

doi:10.1371/journal.pone.0031257.t001

Figure 1. IFN-γ and IL-4 ELISA per 2.5×10^6 PBMCs in carriers and non carriers of the CCR5Δ32 genotype. Levels of IFN-γ and IL-4 after stimulation from carriers (n = 10) and non carriers (n = 9) are shown. Horizontal lines represent the medians.
doi:10.1371/journal.pone.0031257.g001
Tregs are not responsible for the differences in Th2 response between CCR5Δ32 carriers and non-carriers.

**Discussion**

In the present study, we demonstrate a skewing of circulating CD4+ and CD8+ T cells towards the Th2 phenotype based on their intracellular cytokine profile after stimulation in ESRD patients carrying the CCR5Δ32 genotype. These data are in line with animal data showing that genetic deficiency of CCR5 results in a shift in immune response towards a Th2 type response, and support the assumption that genetic differences in immune response are involved in the protection against inflammation-associated mortality in ESRD patients reported previously [4].

In ESRD patients, cardiovascular disease is a main cause of premature deaths [19]. Chronic inflammation is a major contributing factor [20,21]. The inflammatory nature of the process of atherosclerosis is nowadays well recognized [22]. In this process T cells play an important role [9–12]. Th1 cells, which produce IFN-γ as the principal cytokine, are thought to be pro-inflammatory and pro-atherogenic and are the most prevalent subtype in atherosclerotic lesions; Th2 cells, with IL-4 as the major cytokine, have the ability to inhibit Th1 differentiation and could therefore be anti-atherogenic. The role of Th17 cells, producing IL-17, in atherosclerosis is not yet clear [23]. So, until now atherosclerotic inflammation is regarded as a Th1 directed Th1/Th2 disequilibrium [12].

To our knowledge, this is the first functional study investigating the Th1/Th2 directed immune response in relation to the CCR5Δ32 genetic variant in human. Animal studies consistently show a more pronounced Th2 immune response during genetic deficiency of CCR5 or pharmacological CCR5 blockade in atherosclerotic and other inflammatory conditions. In diet-induced atherosclerotic inflammation in mice, genetic deletion of CCR5 was associated with a more stable plaque phenotype and reduced Th1 type immune response of stimulated splenocytes and an increased Th2 type response in splenocytes and lymph node cells [14]. After wire injury in mice with CCR5 deficiency a more atheroprotective immune response was seen, i.e. low IFN-γ and elevated IL-10 in CD4+ splenocytes compared to CCR5 wild type mice [15]. Also in genetically CCR5 deficient mice with diet-induced atherosclerosis, reduced lesion size, increased IL-10 and decreased TNF-α production by CD4+ and CD8+ T cells [16], and reduced macrophage accumulation in plaques and lowered circulating IL-6 levels was seen [17]. In CCR5 deficient mice a more CD4+ Th2 cell activation pattern was seen in colitis in contrast to CCR5 wild type mice [24]. Interestingly, in CCR5 genetically deficient mice who received a renal allograft less Th1
associated markers and increased Th2 associated markers were found during chronic intragraft immune response [25]. In an islet transplantation model it was shown that in genetically CCR5 deficient mice not only in the intragraft immune response but also in the periphery a Th2 shift occurred [26]. In mice with diet-induced atherosclerosis treatment with a RANTES chemokine antagonist, hereby blocking CCR5, reduced atherosclerotic plaque formation, associated with reduced proliferation and secretion of Th1 cytokines IFN-γ and TNF-α, without difference in Th2 cytokine profile [27]. In rats pharmacological CCR5 blockade in stimulated endothelial cells inhibited selective transmigration of CD4+ Th1 cells [28].

Our results extend these animal data on functional differences in immune response for the first time to a human setting and support our previous human cross-sectional association study, showing absence of association between serum CRP and TNF-α
levels in ESRD patients carrying the CCR5Δ32 genotype, in contrast to patients without this genetic variant, supporting a reduced Th1 immune response in CCR5Δ32 [29]. It should be emphasized that ELISA and flowcytometry methods give different types of results and that measuring the intracellular cytokine production by FACS is more accurate than ELISA. The measured cytokines by ELISA can be released from several cells, whereas FACS-method identifies the intracellular cytokines produced on a single-cell level. In addition, difference in T cell numbers between the study samples may influence the results obtained from ELISA but not from FACS method hereby probably explaining why we did not find a difference in extracellular cytokine levels between CCR5Δ32 carriers and non carriers. Since Tregs are responsible for regulation and suppression of T cell responses [9,12], one may argue that differences in Tregs could underlie the increase in IL-4 expression in CCR5Δ32 carriers. However, no significant differences were observed in the percentages of Tregs between CCR5Δ32 carriers and non carriers. Thus, the increased Type 2 response in CCR5Δ32 carriers cannot be related to different frequencies of Tregs.

Together, these findings provide an explanation for the previously observed protection from inflammation-related mortality in ESRD in CCR5Δ32 carriers, as they support a less pro-inflammatory, pro-atherogenic immune response in carriers of the deletion [4]. Our results could also provide a mechanism underlying the protection against atherosclerosis by pharmacological blockade of the CCR5 pathway in animal studies [30–32]. Of note, CCR5 blockade has become feasible in humans, and is currently used for treatment of HIV-infection [33]. It has been proposed that CCR5 blockade may be a strategy for protection against inflammation driven cardiovascular disease in ESRD and/or transplantation [34, 35]. Our current results contribute to understanding of mechanisms that could be affected by CCR5 blocking agents in ESRD.

Limitations

Acknowledged limitation in this study is the relatively small sample size. Besides this one blood sample failed to be stimulated. However, as mentioned above, the results are in accordance with animal data and extend the findings of a correlation study in ESRD patients, supporting the robustness of our findings. Another limitation is that we studied ESRD patients only. ESRD as such affects T-cell properties [36]. Whereas the effects of CCR5 deficiency appear to be remarkably consistent across different species and inflammatory conditions, nevertheless generalization of our results to other populations would require a separate study.

In conclusion, we present the first human data on a difference in Th1/Th2 balance dependent on the CCR5Δ32 genotype in ESRD patients. Stimulated CD4+ and CD8+ T cells of patients with one or two CCR5Δ32 alleles show an increased Th2 type phenotype base on their intracellular cytokine profile. Differences in immune response may be involved in the impact of CCR5Δ32 on outcome in ESRD, and possible other inflammatory conditions.

Author Contributions

Conceived and designed the experiments: FM WA MH JW. Performed the experiments: FM WA MH. Analyzed the data: FM WA JD GN JW. Contributed reagents/materials/analysis tools: FM WA MH JD MS SL BH GN JW. Wrote the paper: FM WA GN JW.

References

1. Rapport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF (1996) Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-Lalpha. J Biol Chem 271(0021-9258; 29): 17161–17166.
2. Wilcox JK, Reiken NA, Goughlin SR, Gordon D, Schall TJ (1994) Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1 Suppl (1340-3478): S10–S13.
3. Benkranze M, Jit DV, Chien RF, Koup RA, Jeang KT (1997) Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 272(0021-9258; 49): 30603–30606.
4. Muntinghe FL, Verduijn M, Zuurman MW, Grootendorst DC, Carrero JJ, et al. (2009) CCR5 deletion protects against inflammation-associated mortality in dialysis patients. J Am Soc Nephrol 20(1533-3450; 7): 1641–1649.
5. Gonzalez P, Alvarez R, Batalla A, Reguero JR, Alvarez V, et al. (2001) Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun 2(1521-7035; 1): 1641–1649.
6. Pai JK, Kraft P, Cannuscio CC, Manson JE, Rexrode KM, et al. (2006) Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5) genes and risk of coronary heart disease among US women. Atherosclerosis 186(0021-9440; 4): 191–195.
7. Szalai C, Duba J, Prohaszka Z, Kalina A, Szabo T, et al. (2001) Involvement of the CCR5 gene in CAD patients. Atherosclerosis 158(0021-9150; 1): 233–239.
8. Muntinghe FL, Gross S, Bakker SJ, Landman GW, van der Harst P, et al. (2009) CCR5Delta32 genotype is associated with outcome in type 2 diabetes mellitus. Diabetes Res Clin Pract 89(1872-2227; 6160-8227; 2): 140–145.
9. Andersson J, Libby P, Hansson GK (2010) Adaptive immunity and atherosclerosis. Clin Immunol 134(1521-7035; 1521-6616; 1): 33–46.
10. Hansson GK (2003) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(1533-4490; 16): 1695–1695.
11. Weber C, Zernecke A, Libby P (2008) The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nat Rev Immunol 8(1474-1741; 10): 802–815.
12. Robertson AK, Hansson GK (2006) T cells in atherosclerosis: For better or for worse? Arterioscler Thromb Vasc Biol 26(1535-2446; 11): 2421–2432.
13. Carter LL, Dutton RW (1996) Type 1 and type 2: A fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8(0952-7915; 0952-7915; 3): 336–342.
14. Braunersreuther V, Zernecke A, Arnaud C, Libien EA, Stellens S, et al. (2007) CCR5 but not CCR1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol 27(1524-4636; 2): 573–579.
15. Zernecke A, Libien EA, Gao JL, Kuziel WA, Murphy PM, et al. (2006) Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice. Involvement of IL-10. Blood 107(0006-4971; 11): 4240–4242.
16. Potters A, Czernichow P, Espinosa B, Lecereuil G, de Oufella H, et al. (2006) Role of bone marrow-derived CC-chemokine receptor 5 in the development of atherosclerosis of low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 26(1524-4636; 8): 1858–1863.
17. Quinones MP, Martinez HG, Jimenez F, Estrada CA, Dudley M, et al. (2007) CC chemokine receptor 5 influences late-stage atherosclerosis. Atherosclerosis 195(1879-1484; 1): e92–103.

18. Clark VJ, McHeny N, Dean M, Peterson RJ (2001) Statistical estimation and pedigree analysis of CCR2-CCR5 haplotypes. Hum Genet 108(0340-6717; 6): 484–493.

19. Degoetle P, Legrain M, Reach I, Aime F, Devries C, et al. (1982) Mortality risk factors in patients treated by chronic hemodialysis. report of the diaphane collaborative study. Nephron 31(0029-2766; 0029-2766; 2): 105–110.

20. Sterminkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, et al. (2005) IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 67(0085-2538; 4): 1216–1233.

21. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, et al. (2004) Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291(1538-3598; 0098-7484; 4): 431–439.

22. Libby P (2002) Inflammation in atherosclerosis. Nature 420(0028-0836; 6917): 868–874.

23. Chen S, Crother TR, Arditi M (2010) Emerging role of IL-17 in atherosclerosis. J Innate Immun 2(1662-8128; 1662-811; 4): 325–333.

24. Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, et al. (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: Lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 164(0022-1767; 12): 6303–6312.

25. Dehmel S, Wang S, Schmidt C, Kiss E, Loewe RP, et al. (2010) Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol 40(1521-4141; 0014-2980; 1): 267–278.

26. Abdi R, Smith RN, Makhoud L, Najafian N, Laster AD, et al. (2002) The role of CC chemokine receptor 5 (CCR5) in islet allograft rejection. Diabetes 51(0012-1797; 0012-1797; 6): 2489–2495.

27. Braunzerreuther V, Steffen S, Arnaud G, Pelli G, Burger F, et al. (2008) A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 28(1524-4636; 1079-5642; 6): 1090–1096.

28. Kawai T, Seki M, Hironatsu K, Eastcott JW, Watts GF, et al. (1999) Selective upregulation of Th1 cells induced by endothelial cell RANTES. J Immunol 163(0022-1767; 6): 3269–3276.

29. Muntinghe FL, Carrero JJ, Nasis G, Stenvinkel P (2011) TNF-alpha levels are not increased in inflamed patients carrying the CCR5 deletion 32. Cytokine 53(1096-0023; 1043-4666; 1): 16–18.

30. Schober A, Manka D, von Hundelshausen P, Hsu Y, Hanrath P, et al. (2002) Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 106(1524-4539; 12): 1523–1529.

31. van Wanrooij EJ, Happe H, Hauer AD, de Vos P, Imamichi T, et al. (2005) HIV entry inhibitor TAK-779 attenuates arterogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25(1524-4636; 12): 2642–2647.

32. Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, et al. (2004) Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 94(1524-4571; 2): 253–261.

33. Farkenheuer G, Pozniak AL, Johnson MA, Plattenberg A, Staszewski S, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11(1078-8956; 11): 1170–1172.

34. Kovesdy CP, Kalantar-Zadeh K (2009) Do genes allow inflammation to kill or not to kill? J Am Soc Nephrol 20(1533-3450; 1533-3450; 7): 1429–1431.

35. Muntinghe FL, Veuger S, Verduin M, Boechsten EW, Dekker FW, et al. (2011) Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenet Genomics 21(7): 417–425.

36. Hendriks TK, van Gurp EA, Mol WM, Schoorl-Dirk J, Sewgoobind JD, et al. (2009) End-stage renal failure and regulatory activities of CD4+CD25brightFoxP+ T-cells. Nephrol Dial Transplant 24(1460-2385; 0931-0509; 6): 1969–1978.